Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Perrone

Showing results (161-170 of 272) with videos related to

Pageof 28
Sort By:
BMJ Open|September 11, 2019
Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocolSilvia Riva, Jane Bryce, Francesco De Lorenzo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2013
Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumabSecondo Lastoria, Maria Carmela Piccirillo, Corradina Caracò, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Tumori|October 18, 2025
Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia MedicaAnna Amela Valsecchi, Matilde Scaldaferri, Marcello Tiseo, et al.
BMJ Oncology|January 31, 2025
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date reviewAlberto Giovanni Leone, Stefania Bonadonna, Chiara Cassani, et al.
The Lancet. Oncology|May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) studyCesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
BMJ Oncology|January 31, 2025
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyLaura Marandino, Federica Trastu, Eleonora Ghisoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancerEmanuela Rossi, Alessandro Morabito, Ermelinda De Maio, et al.
Plos One|January 9, 2019
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodologyGiacomo Pascarella, Arturo Capasso, Antonio Nardone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trialsMassimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
Pageof 28

Showing results (161-170 of 272) with videos related to

Sort By:
Pageof 28
BMJ Open|September 11, 2019
Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocolSilvia Riva, Jane Bryce, Francesco De Lorenzo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2013
Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumabSecondo Lastoria, Maria Carmela Piccirillo, Corradina Caracò, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Tumori|October 18, 2025
Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia MedicaAnna Amela Valsecchi, Matilde Scaldaferri, Marcello Tiseo, et al.
BMJ Oncology|January 31, 2025
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date reviewAlberto Giovanni Leone, Stefania Bonadonna, Chiara Cassani, et al.
The Lancet. Oncology|May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) studyCesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
BMJ Oncology|January 31, 2025
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyLaura Marandino, Federica Trastu, Eleonora Ghisoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancerEmanuela Rossi, Alessandro Morabito, Ermelinda De Maio, et al.
Plos One|January 9, 2019
Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodologyGiacomo Pascarella, Arturo Capasso, Antonio Nardone, et al.
European Journal of Cancer (Oxford, England : 1990)|January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trialsMassimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
Pageof 28